ATE406892T1 - Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil - Google Patents

Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil

Info

Publication number: ATE406892T1
Authority: AT; Austria
Prior art keywords: gemcitabine; uracil; fluoro; preparations containing; combination preparations
Prior art date: 2001-04-06

Application number

AT02726710T

Other languages

English (en)

Inventor

James Gibbons

Gary Dukart

Jurgen Frisch

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-06

Filing date

2002-04-05

Publication date

2008-09-15

2002-04-05 Application filed by Wyeth Corp filed Critical Wyeth Corp

2008-09-15 Application granted granted Critical

2008-09-15 Publication of ATE406892T1 publication Critical patent/ATE406892T1/de

Links

GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title abstract 2
229960002949 fluorouracil Drugs 0.000 title abstract 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 2
229960002930 sirolimus Drugs 0.000 title abstract 2
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title 1
229940046044 combinations of antineoplastic agent Drugs 0.000 title 1
229960005277 gemcitabine Drugs 0.000 title 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title 1
238000002360 preparation method Methods 0.000 title 1
229960000235 temsirolimus Drugs 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 1
230000000340 anti-metabolite Effects 0.000 abstract 1
229940100197 antimetabolite Drugs 0.000 abstract 1
239000002256 antimetabolite Substances 0.000 abstract 1
229940034982 antineoplastic agent Drugs 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
229940124302 mTOR inhibitor Drugs 0.000 abstract 1
239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT02726710T 2001-04-06 2002-04-05 Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil ATE406892T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28238801P	2001-04-06	2001-04-06
US28238501P	2001-04-06	2001-04-06

Publications (1)

Publication Number	Publication Date
ATE406892T1 true ATE406892T1 (de)	2008-09-15

Family

ID=26961412

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02726710T ATE406892T1 (de)	2001-04-06	2002-04-05	Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil

Country Status (21)

Country	Link
EP (1)	EP1385551B1 (de)
JP (1)	JP2004525950A (de)
KR (1)	KR100862178B1 (de)
CN (1)	CN1309421C (de)
AT (1)	ATE406892T1 (de)
AU (1)	AU2007242958A1 (de)
BR (1)	BR0208627A (de)
CA (1)	CA2442849A1 (de)
DE (1)	DE60228699D1 (de)
EA (1)	EA010184B1 (de)
ES (1)	ES2312568T3 (de)
HU (1)	HUP0304093A3 (de)
IL (1)	IL157898A0 (de)
MX (1)	MXPA03009092A (de)
NO (1)	NO20034433L (de)
NZ (1)	NZ540047A (de)
PL (1)	PL363991A1 (de)
PT (1)	PT1385551E (de)
SG (1)	SG152906A1 (de)
SI (1)	SI1385551T1 (de)
WO (1)	WO2002080975A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100600550B1 (ko)	2000-10-20	2006-07-13	에자이 가부시키가이샤	질소 함유 방향환 유도체
CN1551767A (zh)	2001-02-19	2004-12-01	��˹��ŵ��	癌症的治疗
GB0124577D0 (en) *	2001-10-12	2001-12-05	Novartis Forschungsstiftung	Novel methods
EP1478648B1 (de)	2002-02-01	2014-04-30	ARIAD Pharmaceuticals, Inc.	Phosphorhaltige verbindungen und deren verwendungen
UA83484C2 (uk) *	2003-03-05	2008-07-25	Уайт	Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
JP4303726B2 (ja)	2003-11-11	2009-07-29	エーザイ・アール・アンド・ディー・マネジメント株式会社	ウレア誘導体およびその製造方法
CA2557504C (en) *	2004-02-26	2020-12-01	The Penn State Research Foundation	Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
WO2006027545A2 (en) *	2004-09-10	2006-03-16	Agency For Science, Technology And Research	Method
US8969379B2 (en)	2004-09-17	2015-03-03	Eisai R&D Management Co., Ltd.	Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
NZ556673A (en)	2005-02-03	2010-03-26	Gen Hospital Corp	Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
JP4989476B2 (ja)	2005-08-02	2012-08-01	エーザイ・アール・アンド・ディー・マネジメント株式会社	血管新生阻害物質の効果を検定する方法
EP3488866A1 (de) *	2005-11-04	2019-05-29	Wyeth LLC	Antineoplastische kombinationen mit mtor-inhibitor, herceptin und/oder hki-272
AU2006315512B2 (en) *	2005-11-14	2012-11-01	Ariad Pharmaceuticals, Inc.	Administration of an mTOR inhibitor to treat patients with cancer
GB0523658D0 (en) *	2005-11-21	2005-12-28	Novartis Ag	Organic compounds
PT2275103E (pt) *	2005-11-21	2014-07-24	Novartis Ag	Inibidores de mtor para o tratamento de tumores endócrinos
JP2009523149A (ja) *	2006-01-12	2009-06-18	ノバルティスアクチエンゲゼルシャフト	ｍＴＯＲ阻害剤および抗葉酸化合物の組み合わせ
EP1880723A1 (de) *	2006-07-14	2008-01-23	Novartis AG	Kombination aus mTOR Inhibitor und Antifolat Verbindung
WO2007106503A2 (en)	2006-03-13	2007-09-20	Osi Pharmaceuticals, Inc.	Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
CA2645633A1 (en) *	2006-04-05	2007-11-01	Novartis Ag	Combinations of therapeutic agents for treating cancer
CN104706637A (zh)	2006-05-18	2015-06-17	卫材R&D管理有限公司	针对甲状腺癌的抗肿瘤剂
JP2009539769A (ja) *	2006-06-02	2009-11-19	アリアドジーンセラピューティクスインコーポレイテッド	カペシタビン併用療法
US20100266590A1 (en) *	2006-08-02	2010-10-21	Demetri George D	Combination therapy
JP5368096B2 (ja)	2006-08-28	2013-12-18	エーザイ・アール・アンド・ディー・マネジメント株式会社	未分化型胃癌に対する抗腫瘍剤
JP5919593B2 (ja) *	2006-10-11	2016-05-18	フージョンアンティボディーズリミテッド	併用療法
CA2669415A1 (en)	2006-11-14	2008-05-22	Ariad Pharmaceuticals, Inc.	Solid dosage form comprising ap23573
EP2116246A1 (de)	2007-01-19	2009-11-11	Eisai R&D Management Co., Ltd.	Zusammensetzung zur behandlung von pankreaskrebs
WO2008093855A1 (ja)	2007-01-29	2008-08-07	Eisai R & D Management Co., Ltd.	未分化型胃癌治療用組成物
EP3417859A1 (de) *	2007-03-07	2018-12-26	Abraxis BioScience, LLC	Nanopartikel mit rapamycin und albumin als antikrebsmittel
AU2008260447B2 (en)	2007-06-01	2013-10-10	Abraxis Bioscience, Llc	Methods and compositions for treating recurrent cancer
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2704000C (en)	2007-11-09	2016-12-13	Eisai R&D Management Co., Ltd.	Combination of anti-angiogenic substance and anti-tumor platinum complex
CA2719134C (en)	2008-03-21	2015-06-30	The University Of Chicago	Treatment with opioid antagonists and mtor inhibitors
ES2531322T3 (es)	2008-06-17	2015-03-13	Wyeth Llc	Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (de)	2008-08-04	2023-11-01	Wyeth LLC	Antineoplastische kombinationen aus neratinib und capecitabin
PT3000467T (pt)	2009-04-06	2023-03-30	Wyeth Llc	Regime de tratamento utilizando neratinib para o cancro de mama
CA2771403C (en)	2009-08-19	2015-02-24	Eisai R&D Management Co. Ltd.	Quinoline derivative-containing pharmaceutical composition
CN102958523B (zh)	2010-06-25	2014-11-19	卫材R&D管理有限公司	使用具有激酶抑制作用的组合的抗肿瘤剂
AU2012246490B2 (en)	2011-04-18	2016-08-04	Eisai R&D Management Co., Ltd.	Therapeutic agent for tumor
JP6038128B2 (ja)	2011-06-03	2016-12-07	エーザイ・アール・アンド・ディー・マネジメント株式会社	レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
JPWO2014098176A1 (ja)	2012-12-21	2017-01-12	エーザイ・アール・アンド・ディー・マネジメント株式会社	キノリン誘導体のアモルファス及びその製造方法
CA2912219C (en)	2013-05-14	2021-11-16	Eisai R&D Management Co., Ltd.	Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EP3187491A4 (de)	2014-08-28	2018-08-01	Eisai R&D Management Co., Ltd.	Hochreines chinolinderivat und verfahren zur herstellung davon
US20180028662A1 (en)	2015-02-25	2018-02-01	Eisai R&D Management Co., Ltd.	Method for Suppressing Bitterness of Quinoline Derivative
KR20240064733A (ko)	2015-03-04	2024-05-13	머크 샤프 앤드 돔 코포레이션	암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en)	2015-06-16	2023-10-10	Eisai R&D Management Co., Ltd.	Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh)	2015-08-20	2021-02-19	卫材R&D管理有限公司	肿瘤治疗剂
TWI828027B (zh)	2016-03-28	2024-01-01	美商英塞特公司	作為tam抑制劑之吡咯并三嗪化合物
CN110072528B (zh)	2017-02-08	2022-04-26	卫材R&D管理有限公司	治疗肿瘤的药物组合物
WO2018212202A1 (en)	2017-05-16	2018-11-22	Eisai R&D Management Co., Ltd.	Treatment of hepatocellular carcinoma
US10633387B2 (en)	2017-09-27	2020-04-28	Incyte Corporation	Salts of TAM inhibitors
ES3031110T3 (en)	2018-06-29	2025-07-04	Incyte Corp	Formulations of an axl/mer inhibitor
PH12022552347A1 (en)	2020-03-06	2024-01-29	Incyte Corp	Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5066493A (en) *	1978-11-03	1991-11-19	American Home Products Corporation	Rapamycin in treatment of tumors
BE877700A (fr) *	1978-11-03	1980-01-14	Ayerst Mckenna & Harrison	Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
KR100483256B1 (ko) *	1997-01-24	2005-04-15	콘파마 아에스	젬시타빈 유도체
TW466112B (en) *	1998-04-14	2001-12-01	Lilly Co Eli	Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same

2002
- 2002-04-05 AT AT02726710T patent/ATE406892T1/de not_active IP Right Cessation
- 2002-04-05 HU HU0304093A patent/HUP0304093A3/hu unknown
- 2002-04-05 SG SG200506382-1A patent/SG152906A1/en unknown
- 2002-04-05 SI SI200230737T patent/SI1385551T1/sl unknown
- 2002-04-05 MX MXPA03009092A patent/MXPA03009092A/es active IP Right Grant
- 2002-04-05 DE DE60228699T patent/DE60228699D1/de not_active Expired - Fee Related
- 2002-04-05 EA EA200301091A patent/EA010184B1/ru not_active IP Right Cessation
- 2002-04-05 CA CA002442849A patent/CA2442849A1/en not_active Withdrawn
- 2002-04-05 KR KR1020037013090A patent/KR100862178B1/ko not_active Expired - Fee Related
- 2002-04-05 BR BR0208627-1A patent/BR0208627A/pt not_active IP Right Cessation
- 2002-04-05 NZ NZ540047A patent/NZ540047A/en unknown
- 2002-04-05 PT PT02726710T patent/PT1385551E/pt unknown
- 2002-04-05 CN CNB028077490A patent/CN1309421C/zh not_active Expired - Fee Related
- 2002-04-05 EP EP02726710A patent/EP1385551B1/de not_active Expired - Lifetime
- 2002-04-05 PL PL02363991A patent/PL363991A1/xx unknown
- 2002-04-05 IL IL15789802A patent/IL157898A0/xx unknown
- 2002-04-05 ES ES02726710T patent/ES2312568T3/es not_active Expired - Lifetime
- 2002-04-05 WO PCT/US2002/010912 patent/WO2002080975A1/en not_active Ceased
- 2002-04-05 JP JP2002579013A patent/JP2004525950A/ja active Pending
2003
- 2003-10-03 NO NO20034433A patent/NO20034433L/no not_active Application Discontinuation
2007
- 2007-12-13 AU AU2007242958A patent/AU2007242958A1/en not_active Withdrawn

Also Published As

Publication number	Publication date
NZ540047A (en)	2007-01-26
IL157898A0 (en)	2004-03-28
SI1385551T1 (sl)	2008-12-31
SG152906A1 (en)	2009-06-29
PT1385551E (pt)	2008-11-03
MXPA03009092A (es)	2004-02-12
DE60228699D1 (de)	2008-10-16
BR0208627A (pt)	2004-03-09
WO2002080975A1 (en)	2002-10-17
EA200301091A1 (ru)	2004-02-26
NO20034433D0 (no)	2003-10-03
EA010184B1 (ru)	2008-06-30
HK1060062A1 (en)	2004-07-30
EP1385551B1 (de)	2008-09-03
KR100862178B1 (ko)	2008-10-09
NO20034433L (no)	2003-11-25
AU2007242958A1 (en)	2008-01-10
KR20040007491A (ko)	2004-01-24
CN1309421C (zh)	2007-04-11
HUP0304093A3 (en)	2008-08-28
CN1545419A (zh)	2004-11-10
HUP0304093A2 (hu)	2004-04-28
ES2312568T3 (es)	2009-03-01
CA2442849A1 (en)	2002-10-17
PL363991A1 (en)	2004-11-29
JP2004525950A (ja)	2004-08-26
EP1385551A1 (de)	2004-02-04

Legal Events

Date

Code

Title

Description

2009-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1385551

Country of ref document: EP

2011-01-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE60228699D1 (de)	2008-10-16	Antineoplastische kombinationspräparate enthaltend cci-779 (rapamycin derivat) zusammen mit gemcitabin oder fluoro-uracil
NO20054133L (no)	2005-10-03	Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor
DE60226666D1 (de)	2008-07-03	Wälz- und Gleitlagerbauteil und Wälzlager
BR0211769A (pt)	2004-07-27	Combinações antineoplásicas
ATE414514T1 (de)	2008-12-15	Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
CY2007019I2 (el)	2017-07-12	Β-αμινο-τετραϋδροϊμιδαζο-(1,2-α)-πυραζινες και τετραϋδροτριαζολο-(4,3-α)-πυραζινες ως αναστολεις της διπεπτιδυλο πεπτιδασης για την αγωγη ή προληψη του διαβητη
NO20052855D0 (no)	2005-06-13	Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
FR2840523B1 (fr)	2005-05-13	Article multicouche absorbant et recurant
DE602004023760D1 (de)	2009-12-03	Kompositstent mit inneren und äusseren stentelementen und anwendungsverfahren
IS7735A (is)	2005-03-10	Bensódíasepín afleiður og lyfjasamsetningar sem innihalda þær.
NO20054244D0 (no)	2005-09-13	Nitrogeninneholdende heterocykliske derivater og legemidler inneholdende de samme som den aktive bestanddel
CY1109119T1 (el)	2014-07-02	Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη
DE60328677D1 (de)	2009-09-17	Stent und stent-prothese
EP1513825A4 (de)	2011-01-05	Antituberkulöses arzneimittel: zusammensetzungen und verfahren
DE602004012891D1 (de)	2008-05-15	Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel
BR0301985B1 (pt)	2013-09-24	copolímero de flúor, artigo e laminado
BRPI0508451A (pt)	2007-07-24	método de tratamento de linfoma não-hodgkin em um mamìfero, usos de uma combinação de cci-779 e rituximab e de uma combinação de um inibidor de mtor e rituximab, produtos contendo cci-779 e rituximab e um inibidor mtor e rituximab, embalagem farmacêutica, e, composição farmacêutica
CY1114133T1 (el)	2016-07-27	ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
PT1228028E (pt)	2005-10-31	Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular
EP1476419A4 (de)	2005-03-30	N-biphenylmethylaminocycloalkancarboxamid-derivative
FR2849769B1 (fr)	2005-10-14	Implant et prothese articulaire le comprenant
AR033012A1 (es)	2003-12-03	Combinaciones antineoplasicas
NO20040175L (no)	2004-03-12	Acylsemikarbazider som cyklinavhengige kineaseinhibitorer anvendelige som anti-kreft- og anti-proliferative midler
BR0208566B1 (pt)	2013-12-24	Derivados de Beta-Carbolina, Seu Uso, e composição Farmacêutica
ITVR20010031A0 (it)	2001-03-12	Uso di epigallocatechin-3-gallato o suoi derivati nella profilassi e nel trattamento delle malattie neurodegenerative.